Laxolan®
INN: ranibizumab
Ranibizumab is a non-glycosylated recombinant protein (antigen-binding (Fab) fragment of the humanized recombinant monoclonal antibody IgG1κ to human vascular endothelial growth factor (VEGF-A)) with a molecular weight of approximately 48 kDa, which is produced in eukaryotic Chinese hamster ovary cells.
When administered intraocularly, ranibizumab selectively interacts with the receptor-binding sites of active isoforms of human endothelial growth factor VEGF-A and inhibits their biological activity, preventing the interaction of vascular growth factors with receptors on the surface of endothelial cells (VEGFR1 and VEGFR2).
Laxolan®, similar to the reference drug, is intended for use in diseases of the fundus and retina, the pathogenesis of which is based on neovascularization with subsequent leakage of fluid, the development of edema and dystrophic disorders leading to loss of vision.
ЛП-№(003691)-(РГ-RU)
- Treatment of neovascular (wet) form of age-related macular degeneration (nAMD).
- Treatment of decreased visual acuity associated with diabetic macular edema (DME).
- Treatment of proliferative diabetic retinopathy (PDR).
- Treatment of decreased visual acuity caused by macular edema (MO) due to retinal vein occlusion (RVO, central retinal vein or its branches).
- Treatment of decreased visual acuity caused by choroidal neovascularization (CNV).